Company Overview Presentation

Phase 1/2 Translational Data on Omidubicel Presented at TCT

Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens J.J. Presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).

Phase 1 GDA-201 Data Presented at TCT

First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Bachanova V. Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Initial Phase 1/2 Data on Omidubicel in Aplastic Anemia Presented at TCT

Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood (UCB) Transplantation for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery

Clara J. Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Phase 1/2 Data on Omidubicel Published in JCO

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo with Nicotinamide

Horwitz M.E., Wease S., Blackwell B., et al. Journal of Clinical Oncology 2019 Feb 10;37(5):367-374.